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( 57 ) ABSTRACT 
The present invention is directed to methods for forming 
microparticles useful for cell seeding and for conjugating 
protein to the surface of the microparticles . The method 
comprises co - injecting an organic solution of PLGA or other 
polymer with an aqueous solution into a flow focusing tube . 
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METHOD OF FORMING MICROPARTICLES 
FOR USE IN CELL SEEDING 
CROSS - REFERENCE TO RELATED 
APPLICATIONS 
[ 0001 ] This application is based on and claims priority to 
U . S . Provisional Application Ser . No . 62 / 318 , 837 , filed on 
Apr . 6 , 2016 , which is incorporated herein by reference in its 
entirety . 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
[ 0002 ] Not applicable . 
BACKGROUND OF THE INVENTION 
1 . Field of the Invention 
[ 0003 ] The present invention is directed to the field of 
microparticle formation for use in growing cells . 
ducted at a speed from 100 to 300 rpm . In yet other aspects 
of the invention , the second aqueous solution is further 
stirred after the introducing step . 
[ 0009 ] In some aspects of the invention , the PLGA 
microparticles are lyophilized . In other aspects of the inven 
tion , the PLGA microparticles are stretched into microdisks 
and microrods . 
[ 0010 ] Other aspects of the invention are directed to a 
method of conjugating a cell binding protein to surfaces of 
poly ( D , L - lactide - co - glycolide ) ( PLGA ) microparticles . In 
some such aspects of the invention , the PLGA micropar 
ticles comprise PLGA - PEG microparticles . In some aspects 
of the invention , the process includes obtaining PLGA 
microparticles formed from the process of claim 1 . The 
PLGA microparticles are suspended in an aqueous buffer 
solution at pH from 5 . 5 to 6 . 5 . The carboxyl groups on the 
surfaces of the PLGA microparticles are activated , and 
protein is added at a pH above 7 . 0 . The protein and PLGA 
microparticles are shaken to conjugate the protein to the 
surfaces of the PLGA microparticles , and unreacted reagents 
are removed . In some aspects of the invention , the shaking 
step is combined with or followed by deaggregating the 
mixture . In other aspects of the invention , the unreacted 
reagents are removed by centrifugation , filtration or combi 
nations thereof [ 0011 ] In some aspects of the invention , the ratio of the 
PLGA microparticles to the buffer solution is 1 : 1 to 25 : 1 
( w / v ) . In other aspects of the invention , the protein is 
selected from the group consisting of fibronectin , gelatin , 
collagen , laminin and peptides . 
[ 0012 ] Additional aspects of the invention , together with 
the advantages and novel features appurtenant thereto , will 
be set forth in part in the description which follows , and in 
part will become apparent to those skilled in the art upon 
examination of the following , or may be learned from the 
practice of the invention . The objects and advantages of the 
invention may be realized and attained by means of the 
instrumentalities and combinations particularly pointed out 
in the appended claims . 
2 . Description of Related Art 
[ 0004 ] Cell therapy is an emerging strategy to replace or 
repair severely damaged tissues with cultured cells . How 
ever , structural supports are required for cells to form the 
tissue . Biodegradable porous polymeric microparticles have 
been studying as scaffolds for cell growth . 
BRIEF SUMMARY OF THE INVENTION 
[ 0005 ] One aspect of the present invention is directed to a 
method for forming microparticles useful for cell seeding . In 
one such aspect , the method includes obtaining an organic 
solution comprising poly ( D , L - lactide - co - glycolide ) 
( PLGA ) , obtaining a first aqueous solution comprising poly 
vinyl alcohol ( PVA ) and obtaining a second aqueous solu 
tion comprising PVA in a higher concentration than said first 
aqueous solution . The organic solution and a carrier stream 
of the first aqueous solution are injected into a flow focusing 
tube to form organic droplets within the carrier stream . The 
carrier stream comprising the organic droplets is introduced 
into the second aqueous solution to form microparticles of 
the PLGA in the second aqueous solution . The organic 
solvent is evaporated and the PVA is removed . 
[ 0006 ] In some aspects of the invention , the ratio of the 
PLGA to the organic solvent is from 1 % ( w / v ) to 25 % ( w / v ) , 
or from 5 % ( w / v ) to 15 % ( w / v ) . In some aspects of the 
invention , the organic solution comprises PLGA and poly 
ethylene glycol ( PEG ) . In some such aspects , the ratio of 
PLGA to PEG is 70 : 1 or greater . 
[ 0007 ] In some aspects of the invention the concentration 
of PVA in the first aqueous solution is from 1 % ( w / v ) to 10 % ( w / v ) , and the concentration of PVA in the second aqueous 
solution is from 1 % ( w / v ) to 10 % ( w / v ) . In other aspects of 
the invention , the ratio of the organic solution to the first 
aqueous solution is 1 : 1 to 1 : 10 , or 1 : 2 to 1 : 4 . In yet other 
aspects of the invention , the ratio of the organic solution to 
the first aqueous solution to the second aqueous solution is 
from 1 : 1 : 5 to 1 : 5 : 25 . 
[ 0008 ] In some aspects of the invention , the introducing 
step comprises submerging an outflow end of the flow 
focusing tube in the second aqueous solution . In other 
aspects of the invention , the introducing step comprises 
stirring the second aqueous solution , which may be con - 
BRIEF DESCRIPTION OF THE DRAWINGS 
[ 0013 ] FIG . 1 depicts scanning electron microscope 
( SEM ) images of PLGA microparticles of ~ 100 um diam 
eter . 
[ 0014 ] FIG . 2A depicts SEM images of PLGA micropar 
ticles . 
[ 0015 ] FIG . 2B depicts SEM images of PLGA - Gelatin 
( Gel ) microparticles . 
[ 0016 ] FIG . 2C depicts SEM images of PLGA - fibernectin ( FN ) microparticles . 
[ 0017 ] FIG . 2D depicts SEM images of PLGA - Gel - FN 
microparticles . 
[ 0018 ] FIG . 2E depicts SEM images of PLGA - polyethyl 
eneglycol ( PEG ) - Gel microparticles . 
[ 0019 ] FIG . 2F depicts SEM images of PLGA - PEG - FN 
microparticles . 
[ 0020 ] FIG . 3 depicts SEM , fluorescence microscopy , and 
Bright field microscopy of PLGA - gelatin disk micropar 
ticles . 
[ 0021 ] FIG . 4 depicts SEM images of rod shaped 
microparticles . 
[ 0022 ] FIG . 5 is a graph of zeta potential of various 
particle types . 
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[ 0023 ] FIG . 6 depicts fluorescence microscope images of 
cell lines grown on various particle types . 
[ 0024 ] FIG . 7 is a graph of cell growth on various particle 
types . 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENT 
[ 0025 ] The present invention is directed to methods of 
forming microparticles useful for cell seeding and for con jugating protein to the surface of the microparticles . 
[ 0026 ] One aspect of the invention is directed to methods 
of forming microparticles using a flow focusing device . The 
method comprises obtaining an organic solution comprising 
a biodegradable and biocompatible polymer , such as poly 
( D , L - lactide - co - glycolide ) ( PLGA ) . Two aqueous solutions 
comprising a surfactant , such as polyvinyl alcohol ( PVA ) , 
are also obtained . The organic solution is co - injected with a 
stream of the first aqueous solution , referred to herein as a 
" carrier ” stream , into a flow focusing tube . The combined 
streams are introduced into the second aqueous solution to 
form microparticles of the PLGA in the second aqueous 
solution . The organic solvent is then evaporated and the PVA 
removed . [ 0027 ] The biodegradable and biocompatible polymer is 
preferably PLGA . However , other polymers , for example 
polycaprolactone ( PCL ) in dichloromethane ( DCM ) , can 
also be used . Also , PLGA may be combined with polyeth 
ylene glycol ( PEG ) or other polymers . The PEG is prefer 
ably physically adsorbed to PLGA microparticles . Although 
PLGA will be referred to in the following description , it 
should be understood that the description also applies to 
other polymers and polymer combinations . [ 0028 ] The organic solvent can generally be any organic 
solvent . Exemplary organic solvents include halogenated 
hydrocarbons ( e . g . chloroform and dichloromethane ) , ethyl 
acetate , acetone , dioxin and tetrahydrofuran . In some 
embodiments , ethyl acetate is used . The ratio of PLGA to 
solvent is preferably 1 % to 25 % ( w / v ) ( e . g . 10 mg / ml to 250 
mg / ml ) , more preferably 5 % to 15 % , and most preferably 
7 % to 12 % . In some embodiments , the PLGA is present at 
200 mg / ml , or approximately 10 % ( w / v ) . When a second 
polymer such as PEG is present , the ratio of PLGA to PEG 
is preferably greater than 70 : 1 ( w / w ) , more preferably 
greater than 80 : 1 ( w / w ) and most preferably around 90 : 1 
( w / w ) . 
[ 0029 ] The aqueous solutions comprise a surfactant . PVA 
is a commonly used surfactant that has been shown to be 
useful in the present invention , although other surfactants 
can also be used . Although PVA will be referred to in the 
following description , it should be understood that the 
description also applies to such other surfactants . 
[ 0030 ] The aqueous solutions can generally comprise any 
aqueous solvent . Water can be used consistent with the 
present invention , and use of reverse osmosis ( RO ) water 
prevents any external debris during microparticle synthesis . 
Two aqueous solutions are provided . The first aqueous 
solution acts as a carrier stream when co - injected with a 
stream of the organic solution . When the organic solution 
and first aqueous solution are co - injected , the organic solu 
tion forms organic droplets within the carrier stream . More 
specifically , when a fixed amount of the organic solution is 
mixed with a larger volume of the first aqueous solution , 
emulsification will spontaneously occur , thus creating 
spherical droplets of the organic solution . The organic 
solvent will then slightly diffuse into the first aqueous 
solution . The mixture is introduced into the second aqueous 
solution , having a higher concentration of PVA , which acts 
a hardening bath to maintain the size of the microparticles . 
If left open to the atmosphere , the organic solvent will 
evaporate out of the mixture , leaving behind spherical 
polymer particles . Several variables can be modulated to 
control the size of these particles . These variables include : 
method of combining the organic and aqueous phases , 
intensity of mechanical agitation upon addition , length of 
agitation time , length of evaporation time , organic solvent , 
polymer species , polymer concentration , emulsifier addi 
tives in the aqueous phase , concentrations of emulsifiers , 
relative amounts of the two phases , ambient conditions , and 
other variables that will be understood by those of ordinary 
skill in the art . 
[ 0031 ] The concentration of PVA in both the first and 
second aqueous solutions is preferably from 1 % to 10 % 
( w / v ) . The concentration of PVA in the second aqueous 
solution may be higher than the concentration of PVA in the 
first aqueous solution Lower PVA concentrations make 
larger microparticles , whereas higher PVA concentrations 
from smaller microparticles . The concentration of PVA in 
the first aqueous solution is preferably less than 5 % , pref 
erably , less than 3 % , more preferably around 1 % ( w / v ) and 
the concentration of PVA in the second aqueous solution is 
preferably greater than 5 % , preferably greater than 8 % , 
more preferably around 10 % ( w / v ) . The first and second 
aqueous solutions may comprise the same surfactant and 
same aqueous solvent . 
[ 0032 ] The organic solution and first aqueous " carrier " 
solution are co - injected into a flow focusing device using 
any suitable method , as will be understood by one of 
ordinary skill in the art . A stream of the organic solution and 
a carrier stream of the first aqueous solution may be co 
injected using a pump ( s ) , such as a two - syringe pump , in 
which the two syringes are filled with the organic solution 
and first aqueous solution , respectively . The pump can 
maintain the flow rate of the solutions , which assists with 
homogeneous production of microparticles . 
10033 ] Co - injecting the organic solution and carrier aque 
ous solution results in the formation of organic droplets in 
the carrier aqueous solution , as described above . The ratio of 
the organic solution to the first aqueous solution is prefer 
ably 1 : 1 to 1 : 10 , more preferably is 1 : 2 to 1 : 4 ( v / v ) . In some 
embodiments , the ratio of the organic solution to the first 
aqueous solution is 3 : 10 ( v / v ) . 
10034 ] The flow focusing tube into which the stream of 
organic solution and carrier stream of carrier aqueous solu 
tion are co - injected can be any tube suitable for such 
purpose . In some embodiments , the tube is from 9 to 12 
inches in length and 0 . 1 to 0 . 4 inches , preferably 0 . 2 to 0 . 3 
inches , in diameter . A Pasteur pipette , such as a 9 inch 
Pasteur pipette , can be used consistent with the invention . 
[ 0035 ] The carrier stream comprising the organic droplets 
can be introduced into the second aqueous solution by any 
suitable method , as will be readily understood by one of 
ordinary skill in the art . In some embodiments , the outflow 
end of the flow focusing tube is submerged in the second 
aqueous solution . The second aqueous solution may be 
stirred during the introducing process . The second aqueous 
solution may be stirred at 100 to 300 rpm , and in some 
embodiments is stirred at around 250 rpm . The time for 
which the introducing step is carried out can vary depending 
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on the v / v ratio and flow rates . In some embodiments , the 
introducing step is carried out for three minutes . The ratio of 
organic solution to the first aqueous solution to the second 
aqueous solution is preferably from 1 : 1 : 5 to 1 : 5 : 25 ( v / v / v ) . 
In some embodiments the ratio is 3 : 10 : 75 ( v / v / v ) . 
[ 0036 ] When the carrier stream comprising the organic 
droplets is introduced into the second aqueous solution , 
microparticles of the PLGA are formed in the second 
aqueous solution . The microparticles are generally spherical 
in shape . The method of the present invention can produce 
PLGA microparticles with varying sizes , including sizes 
ranging from 100 - 300 um , including 150 - 250 um . 
[ 0037 ] After the carrier stream is introduced into the 
second aqueous solution , the solution can be further stirred 
for a period of time . For example , the second aqueous 
solution can be stirred for 15 to 60 minutes after the carrier 
stream is introduced . 
[ 0038 ] The organic solvent is then evaporated . The solvent 
may be evaporated at room temperature . In such embodi 
ments , the evaporation is preferably carried out for 18 or 
more hours . 
[ 0039 ] The process also preferably includes removing the 
PLA . In some embodiments , the PLA is removed by cen 
trifugation , which may be followed by water washes . The 
remaining PLGA microparticles may then be lyophilized . 
[ 0040 ] In certain applications it is desirable to produce 
PLGA microparticles with different shapes . Non - spherical 
PLGA microparticles can be produced by stretching the 
PLGA microparticles into microdisks and microrods . 
Stretching can be carried out according to the methods 
described in Ho , C . C . , et al . : Preparation of monodisperse 
ellipsoidal polystyrene particles . Colloid and Polymer Sci 
ence , 271 , 469 - 479 ; Champion , J . A . ; Mitragotri , S . : Role of 
target geometry in phagocytosis . Proceedings of the 
National Academy of Sciences of the United States of 
America 2006 , 103 , 4930 - 4934 ; and Barua , S . , et al . : Particle 
shape enhances specificity of antibody - displaying nanopar 
ticles . Proceedings of the National Academy of Sciences of 
the United States of America 2013 , 110 , 3270 - 3275 which 
are incorporated herein for purposes of such disclosure . 
[ 0041 ] A second aspect of the invention is directed to a 
method of conjugating a cell binding protein to surfaces of 
microparticles . The process can be used with the micropar 
ticles formed by the process of the present invention , or with 
biodegradable soft polymeric microparticles formed by 
other processes . Although PLGA microparticles will be 
referred to in the following description , it should be under 
stood that the description also applies to other micropar 
ticles . 
0042 ] Microparticles , such as the PLGA microparticles 
formed from the process described above , are suspended in 
an aqueous buffer solution . The buffer solution preferably 
has a pH from 5 . 5 to 6 . 5 , preferably 5 . 7 to 6 . 3 and in some 
embodiments , around 6 . 0 . The ratio of the PLGA micropar 
ticles to the buffer solution can be 1 : 1 to 25 : 1 ( w / v ) , 5 : 1 to 
15 : 1 , and in some embodiments around 10 : 1 ( w / v ) . Any 
suitable buffer may be used , as will be readily understood by 
one of ordinary skill in the art . A buffer comprising ( mor 
pholino ) ethanesulfonic acid ( MES ) and NaCl is suitable for 
use with the invention . In some embodiments , 50 mg of 
PLGA microparticles may be suspended in 5 ml of an 
aqueous activation buffer comprising 0 . 1 M 2 - mES and 0 . 5 
M NaCl with an adjusted pH of 6 . 0 . 
[ 0043 ] The carboxyl groups on the surfaces of the PLGA 
microparticles are then activated . The activation may 
include addition of synthetic groups such as isothiocyanates , 
isocyanates , acyl azides , NHS esters , sulfonyl chlorides , 
aldehydes , glyoxals , epoxides , oxiranes , carbonates , aryl 
halides , imidoesters , carbodiimides , anhydrides , and fluoro 
phenyl esters , or other suitable groups , as will be readily 
understood by one of ordinary skill in the art . In some 
embodiments , the carboxyl groups are activated by succes 
sive additions of 1 - Ethyl - 3 - ( 3 - dimethylaminopropyl ) carbo 
diimide ( EDC ) and N - hydroxysuccinimide ( NHS ) to pro 
duce an amine - reactive NHS ester on the surfaces of the 
PLGA microparticles . For example , activation of carboxyl 
groups on the PLGA microparticle surface can be accom 
plished through the successive additions of 4 mg of EDC and 
6 mg of NHS to yield an amine - reactive NHS ester . 
[ 0044 ] The protein is then added to form a mixture of the 
microparticles and the protein . Prior to addition of the 
protein the pH is adjusted , preferably to above 7 . 0 , more 
preferably to above 7 . 2 and in some embodiments to around 
7 . 4 . Prior to adding the protein , a portion of the buffer 
comprising a mass of the microparticles in the desired 
amount may be removed from the buffer solution for protein 
addition . The protein may be any cell binding protein , as will 
be recognized by one of ordinary skill in the art . Suitable 
proteins include fibronectin , gelatin , collagen , laminin and 
peptides . In some embodiments , the ratio of protein to 
microparticles can be 0 . 01 : 1 to 1 : 1 , and in some embodi 
ments is around 0 . 05 : 1 ( w / w ) . Fibronectin is a natural 
glycoprotein originating on the extracellular matrix of 
embryonic and adult tissues that binds to the aß , receptor 
on cell surface . Fibronectin aids in cell adhesion through 
specific receptor ligand interactions . It helps wound healing 
with the help of adherent fibroblast cells , fibrin cross - linker 
and collagen fibrils . 
[ 0045 ] The mixture is then shaken to conjugate the protein 
to the surfaces of PLGA microparticles . At lower tempera 
tures , longer incubation times are required . For example , at 
4° C . , the shaking may be carried out for 10 hours , whereas 
at 25° C . , the reaction time could be reduced down to 2 
hours . The shaking may be carried out at around 450 rpm . 
The mixture may be deaggregated , for example by using 
polyethylene glycol ( PEG ) to the mixture . PEG may be 
added to a final concentration of 0 . 001 % PEG . 
[ 0046 ] Unreacted reagents may then be removed . 
Removal of unreacted reagents can be accomplished using 
centrifugation , filtration or combinations thereof , and may 
be accompanied by water washes to achieve pure , protein 
conjugated microparticles . 
[ 0047 ] The present invention provides a new method of 
polymer microparticle synthesis , and non - spherical 
microparticle formation for growing cells on the surface of 
microparticles . The present invention enables synthesis of 
PLGA microparticles of a desired size ( e . g . 150 - 200 um ) 
using a single emulsion solvent evaporation method which 
utilizes a flow - focusing device . Using the flow - focusing 
devices facilitates production of particles of desired size , in 
a short amount of time . It has been found 150 mg of 
microparticles in the 150 - 200 um range can be produced in 
under two hours , whereas other existing methods have had 
trouble reaching this size of particle and have required over 
24 hours for production . The process of the invention can be 
scaled up tenfold to produce 1 . 5 g of particles by increasing 
the poly ( vinyl alcohol ) ( PVA ) hardening bath to 1 L , and the 
US 2017 / 0292109 A1 Oct . 12 , 2017 
time required would not increase . The microparticle synthe - 
sis method of the invention does not require a custom - built 
apparatus or chemically complex solutions ( e . g . salt / protein 
solutions for stabilization of double emulsions , or room 
temperature ionic liquids ) . Additionally , multiple syntheses 
could be conducted in tandem to increase production dra 
matically , while still minimizing personnel . Particles are 
currently produced at a rate of 2000 particles per dollar . 
[ 0048 ] . The method of the present invention prepares 
layer - by - layer microparticles with a PLGA core , and 
fibronectin ( or other protein ) and / or polyethylene glycol 
polymer on the surface of the PLGA , using one - step single 
emulsion . Conventional batch emulsification requires at 
least two steps in which internal droplets of particles are 
formed in surfactant 1 at step 1 for at least 24 h followed by 
outer droplet formation by shear at step 2 with an additional 
24 h . In the method of the present invention , both surfactant 
and particle mixtures are added at the same time in less than 
an hour . The parallel streams of particles and surfactants are 
focused through a constriction that breaks up into droplets 
through the gap . 
[ 0049 ] The present invention can produce particle geom 
etries that are important for eliciting cell alignment to dictate 
tissue microarchitectures and biological functions . The 
aligned organization of cells is important to regulate cell 
matrix organization . As described in Example 3 , below , the 
PLGA microparticles with three different topographical 
geometries where shown to proliferate in an in vitro biore 
actor that provides an effective approach to provide appro 
priate cushioning for cell survival . While there has been an 
interest in growing cells on various shapes of microparticles , 
synthesis of monodisperse spherical PLGA microparticles 
and non - spherical shape PLGA particles has been a chal 
lenge . The invention includes a new technique that can be 
used in spherical and non - spherical microparticle synthesis . 
[ 0050 ] Certain aspects of the invention are illustrated by 
the following non - limiting examples . 
removed , and the emulsion was stirred for an additional 15 
minutes . The mixture was left undisturbed overnight ( > 18 
hours ) to allow for evaporation of residual ethyl acetate at 
room temperature . PVA was removed by centrifugation at 
7 , 000 rcf , followed by five washes with RO water . Micro 
spheres were then lyophilized , weighed , and stored at 4° C . 
PLGA microspheres were stretched to microdisks and 
microrods by the film stretching technology . 
[ 0054 ] Synthesis of PLGA - PEG Microparticles 
10055 ] PLGA - PEG microparticles were prepared using a 
modified version of the single emulsion - solvent evaporation 
technique , utilizing a flow - focusing apparatus as described 
above . PLGA particles with physically adsorbed PEG were 
prepared in the same manner but at a PLGA : PEG ( w / w ) ratio 
of 90 : 10 , thus 180 mg of PLGA and 20 mg of PEG were 
used . An aqueous solution comprising of 1 % ( w / v ) polyvi 
nyl alcohol ( PVA ; Sigma - Aldrich , 30 - 70 kDa , 87 - 90 % 
hydrolyzed ) was formed by dissolving PVA in reverse 
osmosis ( RO ) water . 
Example 2 : Protein ( Fibronectin or Gelatin ) 
Conjugation to the Surface of PLGA and 
PLGA - PEG Microparticles 
[ 0056 ] Bovine fibronectin ( R & D Systems ) and gelatin 
were conjugated to the surface of PLGA microparticles , 
including PLGA - PEG microparticles , by coupling primary 
amines of fibronectin with carboxyl groups of PLGA to form 
amide bonds ( NHS and Sulfo - NHS Instructions , Thermo 
Scientific ) . Briefly , 50 mg of microparticles were suspended 
in 5 ml of an aqueous activation buffer : 0 . 1 M 2 - mor 
pholino ) ethanesulfonic acid ( MES ; Sigma - Aldrich ) and 0 . 5 
M NaCl ( Fisher Scientific ) with an adjusted pH of 6 . 0 . 
Activation of carboxyl groups on the PLGA microparticle 
surface was accomplished through the successive additions 
of 4 mg of 1 - Ethyl - 3 - ( 3 - dimethylaminopropyl ) carbodiimide 
( EDC ; Thermo Scientific ) and 6 mg of N - hydroxysuccin 
imide ( NHS ; Thermo Scientific ) to yield an amine - reactive 
NHS ester . After increasing the mixture pH above 7 . 0 , a 
volume containing the desired particle mass for cell seeding 
was removed , and fibronectin and gelatin were added to this 
volume at a ratio of 0 . 05 mg fibronectin / mg particles . This 
mixture was shaken overnight ( > 10 hours ) at 450 rpm and 4° 
C . 
Example 1 : Microparticle Formation 
[ 0051 ] Synthesis of PLGA Microparticles 
[ 0052 ] Firstly , an organic solution was formulated by 
dissolving 200 mg of Poly ( D , L - lactide - co - glycolide ) 
( PLGA ; Acros Organics , ~ 19 kDa ) in 3 ml of ethyl acetate 
( Fisher Scientific ) . Aqueous solutions of 1 % and 10 % ( w / v ) 
polyvinyl alcohol ( PVA ; Sigma - Aldrich , 30 - 70 kDa ) were 
formed by dissolving PVA in reverse osmosis ( RO ) water . A 
flow - focusing apparatus was assembled with 3 and 10 ml 
syringes , a two - syringe pump ( kdScientific , KDS - 200 ) , plas 
tic tubing , a Pasteur pipette , and a stir plate . The 3 and 10 ml 
syringes were completely filled with the PLGA and 1 % PVA 
solutions , respectively ; these represent the organic and the 
aqueous carrier streams of the flow - focusing apparatus . [ 0053 ] By using an equal drive block velocity on both 
syringes , the two streams were injected into the Pasteur 
pipette at a 3 : 10 flow rate differential . With careful adjust 
ments , gently forcing the organic stream tubing into the 
pipette neck produced regularly - sized organic droplets sur 
rounded by the aqueous carrier stream in the pipette capil 
lary . The Pasteur pipette was positioned vertically above 75 
ml of the 10 % PVA solution ( stirring at approximately 250 
rpm ) such that the pipette tip was just submerged near the 
center of the solution ' s vortex whorl . For 3 minutes of 
injection , the organic droplets were dispersed into the con - 
tinuous aqueous phase . The Pasteur pipette was then 
[ 0057 ) Todisperse aggregations formed during the shaking 
process , and sufficient polyethylene glycol ( PEG ; USP ) was 
added to make the mixture 0 . 001 % PEG . Unreacted reagents 
were removed by centrifugation at 1 , 000 rcf , followed by 3 
washes with sterilized RO water , and subsequent filtration 
through a 100 kDa filter ( EMD Millipore Amicon Ultra - 4 ) . 
The supernatants were combined , and unconjugated 
fibronectin was quantified with the Bradford protein assay 
( Thermo Scientific ) using bovine serum albumin ( BSA ) as 
the standard . Fibronectin - conjugated particles were stored in 
PBS at 4° C . and used for cell seeding within one week . 
Example 3 : Microparticle Characterization 
[ 0058 ] The shape , size , and surface topography of 
microparticles were analyzed with SEM at 1 - 10 kV and 
150x to 250x magnification ( Hitachi S - 4700 ) and stereo 
microscopy ( Hirox KH - 8700 ) . Particle size and shape were 
also visualized with bright field microscopy ( Nikon Eclipse 
E400 ) . The microparticle surface charge was measured in 
water and phosphate buffer saline ( PBS ; Fisher Scientific ) 
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zeta potential of the microparticles was determined using a 
Nanoseries Zetasizer . Zeta potential was measured by dilut 
ing particles to a concentration of 3 mg / ml and measuring 
the electrophoretic mobility of the particles in RO water and 
phosphate buffered saline ( PBS ) . Standard deviation was 
determined by n = 3 trials for each microparticle . Results are 
shown in Table 3 , below and FIG . 5 . The zeta potential was 
found to be - 25 . 9 + 4 . 8 mV in deionized water ( DI H2O ) and 
- 6 . 3 11 . 8 mV in PBS of pH 7 . 4 . 
TABLE 3 
Zeta Potential of Particle Types 
Particle $ ( mV ) in H , 0 $ ( mV ) in PBS 
with dynamic light scattering ( DLS ; Malvern NanoSeries 
Zetasizer ZS90 ) . DLS measurements were performed at 25° 
C . in disposable capillary cells ( Malvern ) using the back 
scattering detection at 90° . The zeta potential was measured 
for 20 successive runs . Data was analyzed using means and 
standard deviations of three measurements . 
10059 ] Results [ 0060 ] SEM images of particle formulations useable in 
cell seeding are shown in FIG . 1 ( PLGA microspheres with 
average particle diameter 183 + 70 um ) , and FIGS . 2A 
( PLGA ) , 2B ( PLGA - Gelatin ( Gel ) ) , 2C ( PLGA - fibernectin ( FN ) ) , 2D ( PLGA - Gel - FN ) , 2E ( PLGA - polyethyleneglycol 
( PEG ) - Gel ) and 2F ( PLGA - PEG - FN ) . FIG . 3 depicts in 
panels ( A ) and ( B ) SEM images of PLGA - Gelatin disk 
shape microparticles of the following dimensions : 81 : 26 
um ; width : ~ 2 surface area ( S . A . ) : ~ 10 , 000 um . Panel ( C ) 
of FIG . 3 depicts results of Fluorescence microscopy of 
FITC dye conjugated PLGA disks , and panel ( C ) depicts 
results of bright field microscopy of PLGA - gelatin disks 
microparticles . FIG . 4 depicts PLGA rod shaped micropar 
ticles of length of ~ 30 um , width 8 + 1 . 7 um , and S . A . of 
~ 570 um ' . [ 0061 ] Adding fibronectin increased particle stability and 
increased particle size significantly . Average particle diam 
eter was determined using ZENPro imaging software which 
was package with the Zeiss Axis confocal microscope . 
Standard deviations were performed with at least n = 50 
particles . Number of particle per gram was determined using 
a known correlation ( REF ) based on polymer density and 
average particle diameter , as shown in Table 1 . 
PLGA 
PLGA - Gel 
PLGA - FN 
PLGA - PEG 
PLGA - PEG - Gel 
PLGA - PEG - FN 
- 25 . 9 + 4 . 80 mV 
- 19 . 9 8 . 02 mV 
- 15 . 1 £ 6 . 9 mV 
- 46 . 3 + 6 . 88 mV 
- 46 . 2 + 6 . 94 mV 
- 42 . 7 + 5 . 64 mV 
- 6 . 26 = 11 . 8 mV 
- 16 . 0 + 18 . 6 mV 
- 27 . 4 + 9 . 89 mV 
- 9 . 49 16 . 9 mV 
- 26 . 0 + 11 . 9 mV 
- 31 . 1 + 13 . 3 mV 
TABLE 1 
Average Particle Diameter and Particle Mass Density 
Average Particle 
Diameter Particle Type No . of Particles / g 
Example 3 : Cell Growth of Microparticles In Vitro 
[ 0064 ] Whether model cell line human umbilical vascular 
endothelial cells ( HUVEC ) attach to microparticles in sus 
pension was investigated . HUVEC were cultured in Medium 
200 containing low serum growth supplement ( LSGS ) and 
1 % penicillin / streptomycin at 37° C . and 5 % CO2 . Cells 
were grown , and sub - cultured using the standard method . To 
this end , the appropriate ratio of cell to particle numbers was 
determined . The surface area ratios of cells to microparticles 
were calculated theoretically . A surface area ratio of 10 was 
reasonable . 1x100 HUVEC were seeded on 10 % number of 
each of disk , rod and spherical shaped microparticles in a 
bioreactor at 37° C . and 5 % CO , . After 24 h , a fluorescence 
microscope using DAPI nuclear stain imaged cell attach 
ment . The number of live cells were quantified , and com 
pared . 
10065 ] FIG . 6 depicts fluorescence microscope images of 
a model cell line ( HUVEC ) , grown on ( a ) a tissue - culture 
treated plate ( control ) ; ( b ) gelatin - coated tissue culture plate 
( control ) ; ( c ) PLGA spheres ; ( d ) PLGA disks ; ( e ) gelatin 
coated PLGA spheres ; and ( f ) collagen - coated PLGA 
spheres . The blue fluorescence indicates cell nuclei . FIG . 7 
is a graph of HUVEC growth on various particle shapes . 
Microparticles enhance the expansion of HUVEC . Disks 
show 1 . 4 fold more HUVEC growth than spheres . The 
attachment of cells to a microparticle surface is often seen as 
PLGA 
PLGA - Gel 
PLGA - FN 
PLGA - PEG 
PLGA - PEG - Gel 
PLGA - PEG - FN 
183 + 70 . 0 um 
214 67 . 0 um 
233 = 37 . 8 um 
161 = 30 . 1 um 
162 = 43 . 3 um 
180 = 42 . 5 um 
222 , 600 
139 , 200 
107 , 850 
326 , 900 
320 , 900 
233 , 900 
[ 0062 ] The conjugation efficiency of fibronectin binding 
to PLGA and PLGA - PEG particles was determined using 
the Bradford Protein Assay . Fibronectin was found to bind 
with 90 % efficiency . Results are shown in Table 2 . Free 
protein describes protein that did not bind to the micropar 
ticle . 
TABLE 2 
Fibronectin conjugation efficiency 
Mass 
Protein Initial 
Mass of Mass Protein 




Protein Density ( ug Protein / 
cm ? Particle ) Particle 
PLGA 
PLGA - PEG 
116 ug 
116 ug 
7 . 02 + 3 . 44 ug 109 3 . 44 ug 94 . 0 + 2 . 97 % 
5 . 13 1 . 03 ug 111 - 1 . 03 ug 95 . 6 0 . 888 % 
28 . 2 + 0 . 890 
22 . 2 - 0 . 206 
[ 0063 ] Fibronectin and gelatin were conjugated to the 
surface of both PLGA and PLGA - PEG particle types to 
improve the particle ' s association with fibroblast cells . The 
a basic characteristic . However , the microparticles geometry 
may subsequently influence and regulate the cell growth and 
survival . 
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[ 0066 ] From the foregoing it will be seen that this inven 
tion is one well adapted to attain all ends and objectives 
herein - above set forth , together with the other advantages 
which are obvious and which are inherent to the invention . 
[ 0067 Since many possible embodiments may be made of 
the invention without departing from the scope thereof , it is 
to be understood that all matters herein set forth or shown in 
the accompanying drawings are to be interpreted as illus - 
trative , and not in a limiting sense . 
[ 0068 ] While specific embodiments have been shown and 
discussed , various modifications may of course be made , 
and the invention is not limited to the specific forms or 
arrangement of parts and steps described herein , except 
insofar as such limitations are included in the following 
claims . Further , it will be understood that certain features 
and subcombinations are of utility and may be employed 
without reference to other features and subcombinations . 
This is contemplated by and is within the scope of the 
claims . 
What is claimed and desired to be secured by Letters 
Patent is as follows : 
1 . A method for forming microparticles useful for cell 
seeding comprising : 
obtaining an organic solution comprising poly ( D , L - lac 
tide - co - glycolide ) ( PLGA ) ; 
obtaining a first aqueous solution comprising polyvinyl 
alcohol ( PVA ) ; 
obtaining a second aqueous solution comprising PVA in a 
higher concentration than said first aqueous solution ; 
co - injecting a stream of the organic solution and a carrier 
stream of the first aqueous solution into a flow focusing 
tube to form organic droplets within the carrier stream ; 
introducing the carrier stream comprising the organic 
droplets into the second aqueous solution to form 
microparticles of the PLGA in the second aqueous 
solution ; 
evaporating the organic solvent ; and 
removing the PVA . 
2 . The method of claim 1 , wherein the ratio of the PLGA 
to the organic solvent is from 1 % ( w / v ) to 25 % ( w / v ) . 
3 . The method of claim 2 , wherein the ratio of the PLGA 
to the organic solvent is from 5 % ( w / v ) to 15 % ( w / v ) . 
4 . The method of claim 1 , wherein the organic solution 
further comprises polyethylene glycol ( PEG ) . 
5 . The method of claim 4 , wherein the ratio of PLGA to 
PEG is greater than 70 : 1 . 
6 . The method of claim 1 , wherein the concentration of 
PVA in the first aqueous solution is from 1 % ( w / v ) to 10 % 
( w / v ) . 
7 . The method of claim 1 , wherein the concentration of 
PVA in the second aqueous solution is from 1 % ( w / v ) to 
10 % ( w / v ) . 
8 . The method of claim 1 , wherein the ratio of the organic 
solution to the first aqueous solution is 1 : 1 to 1 : 10 . 
9 . The method of claim 8 , wherein the ratio of the organic 
solution to the first aqueous solution is 1 : 2 to 1 : 4 . 
10 . The method of claim 1 , wherein the ratio of the 
organic solution to the first aqueous solution to the second 
aqueous solution is from 1 : 1 : 5 to 1 : 5 : 25 . 
11 . The method of claim 1 , further comprising after said 
introducing step , stirring the second aqueous solution . 
12 . The method of claim 1 , further comprising after said 
removing step , lyophilizing the PLGA microparticles . 
13 . The method of claim 1 , further comprising after said 
removing step , the step of stretching the PLGA micropar 
ticles into microdisks and microrods . 
14 . A method of conjugating a cell binding protein to 
surfaces of poly ( D , L - lactide - co - glycolide ) ( PLGA ) 
microparticles comprising : 
obtaining PLGA microparticles formed from the process 
of claim 1 ; 
suspending the PLGA microparticles in an aqueous buffer 
solution at pH from 5 . 5 to 6 . 5 ; 
activating carboxyl groups on the surfaces of the PLGA 
microparticles ; 
adding the protein to form a mixture of the microparticles 
and the protein at a pH above 7 . 0 ; 
shaking the mixture to conjugate the protein to the sur 
faces of the PLGA microparticles ; and 
removing unreacted reagents . 
15 . The method of claim 14 , wherein the ratio of the 
PLGA microparticles to the buffer solution is 1 : 1 to 25 : 1 
( w / v ) . 
16 . The method of claim 14 , wherein the protein is 
selected from the group consisting of fibronectin , gelatin , 
collagen , laminin and peptides . 
17 . The method of claim 14 , wherein the PLGA micropar 
ticles comprise PLGA - PEG microparticles . 
18 . The method of claim 14 , wherein said removing step 
comprises centrifugation , filtration or combinations thereof . 
19 . A method of conjugating a cell binding protein to 
surfaces of poly ( D , L - lactide - co - glycolide ) ( PLGA ) 
microparticles comprising : 
obtaining PLGA microparticles ; 
suspending the PLGA microparticles in an aqueous buffer 
solution at pH from 5 . 5 to 6 . 5 ; 
activating carboxyl groups on the surfaces of the PLGA 
microparticles ; 
adding the protein at a pH above 7 . 0 ; 
shaking the PLGA microparticles and protein to conjugate 
the protein to the surfaces of the PLGA microparticles ; 
and 
removing unreacted reagents . 
20 . The method of claim 19 , wherein the PLGA micropar 
ticles comprise PLGA - PEG microparticles . 
* * * * 
